FDA Approved: APTIVUS — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Aptivus (tipranavir) filed by Boehringer Ingelheim, resulting in a modification to the product label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Aptivus (tipranavir)

Snippet

SUPPL AP for APTIVUS (TIPRANAVIR)